Dihexa is a synthetic peptide built in an academic laboratory as an orally active analog of angiotensin IV, and the honest bottom line is that its scientific reputation now rests on work that has been retracted. The two papers establishing its hepatocyte growth factor mechanism and its headline potency figures were retracted in April 2025, and the compound has never completed a published human clinical trial.
Dihexa has no published human clinical trial and no regulatory approval in any jurisdiction, and its two foundational mechanism papers were retracted in April 2025.
The molecule started as a fix for a specific failure: angiotensin IV improves memory in rodents when delivered directly into brain ventricles, but peptidases destroy it within minutes and it does not cross the blood-brain barrier in meaningful amounts. Joseph Harding's laboratory at Washington State University stripped that fragment to its active core and capped both ends so it would survive the gut. The compound that later reached consumers as a nootropic was never designed for that market; vendors picked it up from preclinical papers written to support further laboratory work.
Dihexa, also designated PNB-0408, is a protease-resistant angiotensin IV analog with the molecular formula C27H44N4O5 and CAS number 1401708-83-5.
The mechanism most often quoted for Dihexa is a mechanistic claim, described in cell and tissue work rather than measured in people. Published work from the originating laboratory reported that the compound binds hepatocyte growth factor and helps it dimerize, which would make it a conditional potentiator rather than a direct receptor agonist. That account now sits in an awkward place, because the two papers that established it were retracted in April 2025.
The HGF binding and dimerization model for Dihexa rests on two Journal of Pharmacology and Experimental Therapeutics papers from 2012 and 2014 that were retracted in April 2025.
Oral activity is the single property that made Dihexa interesting as a drug candidate rather than a laboratory curiosity, and rodent work from the originating group reported measurable brain concentrations and behavioral effects after oral dosing. What sits behind that headline is close to empty. No human absorption, half-life, distribution, metabolism, or clearance figures have been published, so no dosing interval for people rests on measured exposure.
No human pharmacokinetic data for Dihexa have been published, so neither an oral dose nor a dosing interval for people can be derived from measured human exposure.
The potency figures circulating in vendor copy come from a cell culture assay, not from a person. The published record for Dihexa reaches animal and in vitro evidence and stops there, and the papers carrying its most quoted results have since been retracted or flagged. The distance between a rodent water maze result and a treatment for human memory loss is the whole of the work that was never done.
Every reported cognitive and spinogenesis effect of Dihexa comes from rodent or cell culture work, and no human clinical trial of the compound has been published.
Dihexa occupies none of the legal categories that would allow it to be sold for human use. It is not an approved drug in the United States or the European Union, not a recognized dietary ingredient, and not eligible for pharmacy compounding, which leaves the research chemical channel and its not-for-human-consumption label as the only route it travels.
| Regulatory pathway | Dihexa | An FDA-approved drug |
|---|---|---|
| Marketing authorization | None in the US or EU | Granted for named indications |
| Dietary supplement eligibility | Not a recognized dietary ingredient | Not applicable |
| Section 503A compounding | Meets none of the three criteria | Component of an approved product |
| Human exposure data on file | None identified by the FDA | Required before approval |
| Anti-doping status | Prohibited in and out of competition | Varies by substance |
Dihexa acetate meets none of the three criteria for section 503A compounding and was placed on the FDA's Category 2 listing, where the agency recorded that it had identified no human exposure data by any route of administration.
There is no safety profile for Dihexa to summarize, which is a different statement from saying the compound is safe. No human trial has characterized its adverse events, no dose-limiting toxicity has been established in people, and no chronic exposure data exist at the durations consumers describe. The theoretical concern that follows from the proposed mechanism is the serious one: HGF and c-Met signaling drive proliferation, migration, and survival, and dysregulated c-Met activity is a recognized feature of several human cancers.
Rodent studies lasting a few weeks cannot detect tumor promotion, so the absence of cancer findings in Dihexa's published animal work is not evidence of safety over years of use.
The only Dihexa dosing figures that came out of an experiment are the ones in the published animal work, where the compound was given orally and by injection. Effective doses in rodent cognition models ran near one to two milligrams per kilogram of body weight per day, over protocols lasting from several days to three months. The dosing charts published by vendors read like clinical guidance and are not: no dose-ranging study underlies them, and they are inconsistent from one seller to the next.
Published rodent protocols used roughly 1 to 2 mg/kg per day for periods ranging from several days to three months, and no equivalent human dose has ever been established.
The research peptide supply chain contains no step that verifies what is in the vial. Bulk material, frequently synthesized overseas, is bought by resellers, repackaged under their own branding, and sold online with no premarket review and no enforced good manufacturing practice requirement. Independent analytical testing across this sector has repeatedly found underdosed products, mislabeled peptides, vials with no detectable active ingredient, and material carrying residual synthesis solvents, bacterial endotoxin, or heavy metal contamination.
A certificate of analysis carries weight only when an accredited independent laboratory has tested the specific lot number on the vial for identity and purity, which seller-supplied certificates frequently cannot demonstrate.
Most nootropics act on neurotransmission and wear off; Dihexa is proposed to act structurally, by potentiating a growth factor pathway that builds new dendritic spines. That is a claim about remodeling brain tissue rather than adjusting its chemistry, and it is the reason the compound draws attention. Measured against the peptides and drugs it gets compared with, though, the difference that matters is evidentiary.
| Compound | Human evidence | Regulatory standing |
|---|---|---|
| Dihexa | None published | Unapproved research chemical |
| Semax and Selank | Decades of Russian clinical use, limited by Western standards | Not approved in the US or EU |
| Cerebrolysin | Multiple controlled trials, mixed results | Not approved in the US |
| Cholinesterase inhibitors, memantine | Modest measured effects in registration trials | FDA-approved for Alzheimer's disease |
| Anti-amyloid antibodies | Defined efficacy and defined risks in trials | FDA-approved with monitoring requirements |
Among commonly compared cognition peptides, Dihexa carries the most striking preclinical potency figures and the only completely absent human trial record.
A decade of preclinical interest with no visible clinical program reads as caution rather than conspiracy. Dihexa's intellectual property moved from Washington State University into private hands and has been attached to early-stage biotechnology work aimed at neurodegenerative disease, but no registered human program for the compound has produced published results. It sits at the beginning of the approval path, not partway along it.
Dihexa has not cleared the first stage of the drug approval path, since no chronic toxicology program, investigational new drug application, or phase 1 human study for the compound has been published.
Educational use only. This article describes what the published scientific and clinical literature reports about Dihexa. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
